(1) Background: Cytoreductive surgery (CRS) with HIPEC is considered the standard of care for selected patients with peritoneal carcinomatosis, but evidence-based treatment recommendations for the therapy of peritoneal sarcomatosis are scarce. (2) Methods: We retrospectively analyzed all adult patients treated with CRS and HIPEC for peritoneal sarcomatosis between 2017 and 2024. (3) Results: Ten patients with a median age of 46.1 years (range: 23–77 years) with metachronous (40%) or synchronous (60%) peritoneal sarcomatosis from six different tumor entities were treated according to tumor board recommendation using CRS and HIPEC with cisplatin and doxorubicin over 60 min at 42.0 °C. The length of stay in the intensive care unit and hospital was 1.24 (0.6–1.9 days) and 11.1 days (6–17 days), respectively. Complete cytoreduction was achieved in 90% of the patients, with a median PSI of 11.5. Postoperative complications occurred in five cases, but no surgical revisions were necessary, and no acute kidney damage was recorded. (4) Conclusions: CRS with HIPEC in the presence of peritoneal sarcomatosis could be safely performed in our collective. Whether this resulted in an oncological treatment benefit cannot be concluded in view of the heterogeneous and small collective. Therefore, larger and prospective studies are warranted.
(1) 背景：细胞减灭术联合腹腔热灌注化疗已成为腹膜癌病患者的标准治疗方案，但针对腹膜肉瘤病的循证治疗建议仍较为缺乏。(2) 方法：本研究回顾性分析了2017年至2024年间接受细胞减灭术联合腹腔热灌注化疗治疗的成年腹膜肉瘤病患者。(3) 结果：共纳入10例中位年龄46.1岁（范围：23-77岁）的患者，其中异时性腹膜转移占40%，同时性转移占60%，涉及六种不同肿瘤类型。所有病例均经多学科会诊讨论后，采用42.0°C条件下持续60分钟的顺铂联合多柔比星腹腔热灌注化疗方案。重症监护室停留时间中位数为1.24天（范围：0.6-1.9天），总住院时间中位数为11.1天（范围：6-17天）。90%患者实现完全细胞减灭，腹膜癌病指数中位数为11.5。5例患者出现术后并发症，但均无需再次手术干预，且未观察到急性肾损伤病例。(4) 结论：本研究表明细胞减灭术联合腹腔热灌注化疗治疗腹膜肉瘤病具有安全性。但由于研究样本量较小且肿瘤异质性显著，该治疗方案能否带来肿瘤学获益尚不明确，仍需开展大规模前瞻性研究加以验证。
肿瘤(癌症)患者之家